( e later in 2007. Phase 1 Trial Resu...)Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO,Health

Phase 1 Trial Results of KOS-1584

The Phase 1 trial was designed to define the maximum tolerated dose, dose- limiting toxicity and recommended Phase 2 dose, and to assess early activity of KOS-1584 when administered to patients with advanced solid tumors (no standard curative therapy options). The Phase 1 trial dose schedules initially included a 1-hour weekly infusion for 3 weeks out of 4, and weekly for 2 weeks out of 3. More recently, a dose schedule of a 3-hour infusion was initiated on both weekly schedules (2 out of 3 weeks, 3 out of 4 weeks) to allow reduced Cmax (reduced peak exposure) with similar overall exposure enabling maximization of dose intensity.

A total of 50 patients have been enrolled in the Phase 1 trial. Indications of antitumor activity were observed in 32% of patients evaluable for efficacy, including,

    -- 1 confirmed partial response (PR) in a patient with advanced non-small

       cell lung cancer (3 prior chemotherapy regimens); this patient had 44%

       tumor shrinkage by RECIST, and withdrew after 10 months (10 cycles)

       while still in PR;

    -- 1 patient with advanced ovarian cancer (4 prior regimens) had 40% CA125

       decline and 20% shrinkage of nodal disease;

    -- 1 patient with advanced prostate cancer had 94% reduction in PSA and

       improved nodal disease after cycle 2 and was on study for 6 months

      (6 cycles); and

    -- Patients with stable disease (3 or more months) include those with head

       and neck, prostate, ovarian, breast, non-small cell lung, colon,

       pancreatic and cervical cancers.

Common drug related toxicities on the 1-hour, 3-week and 4-week schedules were similar and were predominantly gastrointestinal symptoms and fatigue.

    -- On the 4-week, 1-hour infusion schedule, dose-limiting toxicity was

       primarily diarrhea observed at 20 and 25 mg/m2; no dose-limiting

       toxicity was observed at
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90
Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory
Breast and Ovarian Cancers at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing
Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity
of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel
Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On
Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor
Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the
Clinical Trial of MediGenes Cancer-Killing Virus in Press
Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes
Association Conference